Favorable effect of Everolimus on cardiac allograft vasculopathy is maintained through 24 months
E. Murat Tuzcu, Jon Kobashigawa, Howard J. Eisen, Randall C. Starling, Tim Crowe, Kamal Abeywickrama, Jonathan S. Jaffe
Abstract
E. Murat Tuzcu, Jon Kobashigawa, Howard J. Eisen, Randall C. Starling, Tim Crowe, Kamal Abeywickrama, Jonathan S. Jaffe
Abstract
An abstract is not available in the OpenAlex record for this paper.
OpenAlex reports 7 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Key concepts: Everolimus, Cardiac allograft vasculopathy, Azathioprine, Medicine, Cardiology, Internal medicine, Urology, Heart transplantation